Comparison of angiographic and IVUS follow-up between the two different drug-eluting stents implanted simultaneously in the same individuals

Journal of Invasive Cardiology

Volumn 24, Issue 8, 2012, Pages 374-378

  Xiang, Dingcheng ^a   Yi, Shaodong ^a   Ruan, Yunjun ^a   Gong, Zhihua ^a   Hong, Changjiang ^a   Qiu, Jian ^a  

^a Liuhuaqiao Hospital   (China)

Author keywords

biocompatible polymer; biodegradable polymer; percutaneous coronary intervention; sirolimus eluting stent; zotarolimus eluting stent

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RAPAMYCIN; ZOTAROLIMUS;

ACUTE HEART INFARCTION; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY ANEURYSM; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; IN STENT LATE LUMINAL LOSS; IN STENT LUMINAL STENOSIS; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; INTRAVASCULAR ULTRASOUND; MALE; PROSTHESIS FAILURE; STABLE ANGINA PECTORIS; STENOSIS; UNSTABLE ANGINA PECTORIS;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; BIOCOMPATIBLE MATERIALS; COMPARATIVE EFFECTIVENESS RESEARCH; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY VESSELS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; POLYMERS; POSTOPERATIVE COMPLICATIONS; SIROLIMUS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84865131376     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Leon MB, Mauri L, Popma JJ, et al. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol. 2010;55(6):543-554.
2. Kandzari DE, Mauri L, Popma JJ, et al. Late-term clinical outcomes with zotarolimus-and sirolimus-eluting stents 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2011;4(5):543-550.
3. Fajadet J, Wijns W, Laarman GJ, et al. Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study. EuroIntervention. 2010;6(5):562-567.
4. Jain AK, Lotan C, Meredith IT, et al. Twelve-month outcomes in patients with diabetes implanted with a zotarolimus-eluting stent: results from the E-Five registry. Heart. 2010;9(11):848-853.
5. Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006;47(1):175-181. (Pubitemid 43005183)
6. Guagliumi G, Farb A, Musumci G, et al. Sirolimus-eluting stent implanted in human coronary artery for 16 months: pathological findings. Circulation. 2003;107(9):1340-1341. (Pubitemid 36314421)
7. Fere F, Costa JR, Abizaid A. Very late thrombosis after drug-eluting stents. Catheter Cardiovasc Interv. 2006;68(1):83-88. (Pubitemid 44024467)
8. Liu HL, Jin ZG, Luo JP, et al. Long-term effects of biodegradable versus durable polymer-coated sirolimus-eluting stents on coronary arterial wall morphology assessed by virtual histology intravascular ultrasound. Chin Med J. 2011;124(6):836-844.
9. Guagliumi G, Sirbu V, Musumeci G, et al. Strut coverage and vessel wall response to a new-generation paclitaxel-eluting stent with an ultrathin biodegradable abluminal polymer: Optical Coherence Tomography Drug-Eluting Stent Investigation (OCTDESI). Circ Cardiovasc Interv. 2010;3(4):367-375.
10. Lemos PA, Moulin B, Perin MA, et al. Rationale and design for the PAINT randomized trial. Arq Bras Cardiol. 2009;93:547-553, 590-597.
11. Dani S, Kukreja N, Parikh P, et al. Biodegradable-polymer-based, sirolimus-eluting Supralimus stent: 6-month angiographic and 30-month clinical follow-up results from the series I prospective study. EuroIntervention. 2008;4(1):59-63.
12. Han Y, Jing Q, Xu B, et al. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. JACC Cardiovasc Interv. 2009;2(4):303-309.
13. Awata M, Uematsu M, Sera F, et al. Angioscopic assessment of arterial repair following biodegradable polymer-coated biolimus A9-eluting stent implantation. Comparison with durable polymer-coated sirolimus-eluting stent. Circ J. 2011;75(5):1113-1119.
14. Guagliumi G, Sirbu V, Musumeci G, et al. Strut coverage and vessel wall response to a new-generation paclitaxel-eluting stent with an ultrathin biodegradable abluminal polymer: Optical Coherence Tomography Drug-Eluting Stent Investigation (OCTDESI). Circ Cardiovasc Interv. 2010;3(4):367-375.
15. Hu D, Li J, Li X. China Cholesterol Education Program. Investigation of blood lipid levels and statin interventions in outpatients with coronary heart disease in China: the China Cholesterol Education Program (CCEP). Circ J. 2008;72(6):2040-2045.
16. Wang ZW, Wang X, Zhang LF, et al. Hypertension Control in Communities (HCC): evaluation result of blood pressure management among hypertensive. Zhonghua Liu Xing Bing Xue Za Zhi. 2010;31(1):1-4.
17. Tahara S, Bezerra HG, Sirbu V, et al. Angiographic, IVUS, and OCT evaluation of the long-term impact of coronary disease severity at the site of overlapping drug-eluting and bare metal stents: a substudy of the ODESSA trial. Heart. 2010;96(19):1574-1578.
18. Guagliumi G, Musumeci G, Sirbu V, et al. Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents. JACC Cardiovasc Interv. 2010;3(5):531-539.
19. Mintz GS, Nissen SE, Anderson WD, et al. American College of Cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies. J Am Coll Cardiol. 2001;37(5):1478-1492.
20. Xu B, Dou KF, Han YL, et al. A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results. Chin Med J (Engl). 2011;124(6):811-816.
21. Tian F, Chen YD, Chen L, et al. Evaluation on the neointimal coverage post drug-eluting stent implantation by optical coherence tomography. Zhonghua Xin Xue Guan Bing Za Zhi. 2011;39(3):204-207.
22. Park SM, Kim JS, Ko YG, et al. Angiographic and intravascular ultrasound follow-up of paclitaxel-and sirolimus-eluting stent after poststent high-pressure balloon dilation: from the poststent optimal stent expansion trial. Catheter Cardiovasc Interv. 20111;77(1):15-21.
23. Doi H, Maehara A, Mintz GS, et al. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials. JACC Cardiovasc Interv. 2009;2(12):1269-1275.
24. Verheye S, Agostoni P, Dubois CL, et al. 9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study. J Am Coll Cardiol. 2009;53(12):1031-1039.
25. Fajadet J, Wijns W, Laarman GJ, et al. Randomized, double-blind, multicenter study of the ENDEAVOR zotarolimus-eluting phosphorylcholine- encapsulated stent for treatment of native coronary artery lesions. Circulation. 2006;114(8):798-806. (Pubitemid 44268230)
26. Hahn JY, Song YB, Choi JH, et al. Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent) registry. Circ J. 2010;74(11):2314-2321.
27. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007;115(6):813-818. (Pubitemid 46294748)
28. Parker T, Davé V, Falotico R. Polymers for drug eluting stents. Curr Pharm Des. 2010;16(36):3978-3988.
29. Xi TF, Gao RL, Xu B, et al. In vitro and in vivo changes to PLGS/sirolimus coating on drug eluting stents. Biomaterials 2010; 31: 5151-8.